这篇研究介绍了一项关于增强癌症免疫疗法的新策略。 研究人员开发了一种名为 TFF2-MSA 的 CXCR4 部分激动剂肽，并发现它能有效地使小鼠胃癌对抗PD-1免疫疗法敏感。 这种联合疗法通过靶向并减少免疫抑制性中性粒细胞 (PMN-MDSCs) 和癌症驱动的粒细胞生成，从而在肿瘤微环境中激活强大的抗肿瘤CD8+T细胞反应。 值得注意的是，TFF2-MSA的作用优于完全的 CXCR4拮抗剂，并且在胃癌患者中，较低的TFF2水平与CXCR4+LOX-1+ PMN-MDSCs 的升高有关，这突显了该策略的潜在临床意义。 总体而言，这项研究提出了一种通过精细调节CXCR4信号来克服中性粒细胞介导的免疫抑制，进而提高免疫治疗效果的方法。References: Qian J, Ma C, Waterbury Q T, et al. A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis[J]. Cancer Cell, 2025.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Trump $82 Million Bond Spree, Brazil Tariffs 'Too High,' More
16 Nov 2025
Bloomberg News Now
Ex-Fed Gov Resigned After Rules Violations, Trump Buys $82 Mil of Bonds, More
16 Nov 2025
Bloomberg News Now
THIS TRUMP INTERVIEW WAS INSANE!
16 Nov 2025
HasanAbi
Epstein Emails and Trump's Alleged Involvement
15 Nov 2025
Conspiracy Theories Exploring The Unseen
New Epstein Emails Directly Implicate Trump - H3 Show #211
15 Nov 2025
H3 Podcast
Trump Humiliates Himself on FOX as They Call Him Out
15 Nov 2025
IHIP News